Technical Analysis for CNTX - Context Therapeutics Inc.
| ADX | Long Term | Intermediate Term | Short Term |
|---|---|---|---|
| Strong | Up | Up | Up |
| Date | Alert Name | Type | % Chg |
|---|---|---|---|
| 20 DMA Support | Bullish | 0.00% | |
| Gapped Up | Strength | 0.00% | |
| Crossed Above 20 DMA | Bullish | 2.18% | |
| NR7 | Range Contraction | 2.18% | |
| Narrow Range Bar | Range Contraction | 2.18% | |
| Inside Day | Range Contraction | 2.18% | |
| Fell Below 20 DMA | Bearish | 8.47% | |
| Crossed Above 20 DMA | Bullish | 0.01% | |
| Gapped Up | Strength | 0.01% | |
| 20 DMA Resistance | Bearish | 3.68% |
| Alert | Time |
|---|---|
| 20 DMA Support | about 11 hours ago |
| 10 DMA Support | about 11 hours ago |
| 60 Minute Opening Range Breakout | about 11 hours ago |
| Up 3% | about 11 hours ago |
| 60 Minute Opening Range Breakdown | about 12 hours ago |
Get this analysis on your stocks daily!
- Earnings date: 05/08/2024
Context Therapeutics Inc. Description
Context Therapeutics Inc., a clinical-stage biopharmaceutical company, develops products for the treatment of cancer for women in the United States. Its lead product candidate is onapristone extended release (ONA-XR), a selective potent antagonist of the progesterone receptor that is linked to resistance for various classes of cancer therapeutics, such as ovarian, uterine (endometrial), and breast cancers. The company also engages in developing CLDN6xCD3 bsAb, an anti-CD3 x anti-Claudin 6 antigen bispecific monoclonal antibody that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6. In addition, it is involved in the development of Sigma1, a cellular protein that regulates homeostasis, which is in clinical studies for the treatment of breast and prostate cancer. Context Therapeutics Inc. has a collaboration and licensing agreement with Integral Molecular, Inc. for the development of CLDN6xCD3 bsAb. The company was founded in 2015 and is based in Philadelphia, Pennsylvania.
Classification
Sector: Healthcare
Industry: Biotechnology
Keywords: Biopharmaceutical Cancer Clinical Medicine Organ Systems Treatment Of Cancer Breast Cancer Antineoplastic Drugs Endocrine System Cancer Therapeutics Antiprogestogens Estranes
| Indicator | Bull Case | Neutral / Hold | Bear Case |
|---|---|---|---|
| 50 DMA | |||
| 200 DMA | |||
| ADX Trend | |||
| Oversold / Overbought | |||
| Relative Strength |
| Indicator | Value |
|---|---|
| 52 Week High | 1.69 |
| 52 Week Low | 0.4703 |
| Average Volume | 66,367 |
| 200-Day Moving Average | 1.12 |
| 50-Day Moving Average | 1.24 |
| 20-Day Moving Average | 1.37 |
| 10-Day Moving Average | 1.39 |
| Average True Range | 0.12 |
| RSI (14) | 55.56 |
| ADX | 42.57 |
| +DI | 24.86 |
| -DI | 12.66 |
| Chandelier Exit (Long, 3 ATRs) | 1.23 |
| Chandelier Exit (Short, 3 ATRs) | 1.60 |
| Upper Bollinger Bands | 1.53 |
| Lower Bollinger Band | 1.22 |
| Percent B (%b) | 0.63 |
| BandWidth | 22.47 |
| MACD Line | 0.04 |
| MACD Signal Line | 0.05 |
| MACD Histogram | -0.011 |
| Pivot Point Level | Traditional / Classic | Fibonacci | Demark | Woodie | Camarilla |
|---|---|---|---|---|---|
| Resistance 4 (R4) | 1.53 | ||||
| Resistance 3 (R3) | 1.53 | 1.49 | 1.51 | ||
| Resistance 2 (R2) | 1.49 | 1.46 | 1.49 | 1.50 | |
| Resistance 1 (R1) | 1.45 | 1.44 | 1.43 | 1.45 | 1.50 |
| Pivot Point | 1.41 | 1.41 | 1.40 | 1.41 | 1.41 |
| Support 1 (S1) | 1.37 | 1.38 | 1.35 | 1.37 | 1.32 |
| Support 2 (S2) | 1.33 | 1.36 | 1.33 | 1.32 | |
| Support 3 (S3) | 1.29 | 1.33 | 1.31 | ||
| Support 4 (S4) | 1.29 |
